| Literature DB >> 30028574 |
Yesid A Ramirez1,2, Thomas B Adler2, Eva Altmann3, Theresa Klemm1, Christian Tiesmeyer1, Florian Sauer1, Stefan G Kathman4, Alexander V Statsyuk5, Christoph Sotriffer2, Caroline Kisker1.
Abstract
Based on the similarity between the active sites of the deubiquitylating and deneddylating enzyme ChlaDub1 (Cdu1) and the evolutionarily related protease adenain, a target-hopping screening approach on a focused set of adenain inhibitors was investigated. The cyanopyrimidine-based inhibitors identified represent the first active-site-directed small-molecule inhibitors of Cdu1. High-resolution crystal structures of Cdu1 in complex with two covalently bound cyanopyrimidines, as well as with its substrate ubiquitin, were obtained. These structural data were complemented by enzymatic assays and covalent docking studies to provide insight into the substrate recognition of Cdu1, active-site pocket flexibility and potential hotspots for ligand interaction. Combined, these data provide a strong basis for future structure-guided medicinal chemistry optimization of this cyanopyrimidine scaffold into more potent and selective Cdu1 inhibitors.Entities:
Keywords: CE proteases; cyanopyrimidines; deubiquitylating enzyme inhibition; reversible covalent inhibitors; target hopping
Mesh:
Substances:
Year: 2018 PMID: 30028574 PMCID: PMC6177307 DOI: 10.1002/cmdc.201800364
Source DB: PubMed Journal: ChemMedChem ISSN: 1860-7179 Impact factor: 3.466